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2 in RIC groups had successful pregnancy. Premature ovarian
failure is less common among patients given RIC regimens than
among those given HDC regimens for HST. Future prospective
study is justiﬁed to determine the overall incidence of POF and the
role of RIC regimens in lowering the treatment-related toxicity.
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Pts with CLL refractory to ﬂudarabine (FLU)-based chemother-
apy have poor prognosis with a median survival of less than 1 year.
We examined the safety and efﬁcacy of NM-HCT for pts with
CLL refractory to at least 1 cytotoxic regimen and ineligible for
conventional allogeneic HCT due to age and/or comorbidities.
Forty-seven pts with diagnoses of CLL (n  42), small lympho-
cytic lymphoma (n  2), or prolymphocytic leukemia (n  3) were
treated with NM-HCT from MRD (n  33) and URD (n  14).
Median pt age was 58 (range 47-68) years (62% of pts 55 years).
Median number of prior regimens was 4 (range 1-12) with 94% of
pts refractory to at least 1 regimen. Thirty-six pts (77%) were
refractory to FLU, 19 to alkylating agents and 6 to rituxumab. Two
pts had prior autologous HCT. Nineteen pts (40%) had responsive
disease to salvage chemotherapy given prior to HCT [partial (PR)
(30%) or complete remission (CR) (10%)] while remaining pts
were either nonresponsive (51%) or in relapse (9%). Median in-
terval from diagnosis to HCT was 5 (0.6–25) years. Conditioning
consisted of 2 Gy TBI alone (n  19) or combined with FLU (n 
28), 90mg/m2 followed by mycophenolate mofetil and cyclosporine
immunosuppression. All pts received G-CSF mobilized peripheral
blood mononuclear cells as source of stem cells. After HCT, all pts
became neutropenic (median ANC nadir30 cells/ul) for a median
of 11 days. Eighteen pts never had platelet counts below 20,000
cells/ul. Three pts had graft rejection; 1 died with aplasia and 2 had
autologous recovery and are alive, 1 after multiple treatments and
1 relapsed at 2 years. Incidences of grades II, III, and IV acute
GVHD were 38%, 15%, and 2% respectively and chronic exten-
sive GVHD was estimated to be 48% at 4 years. With median
follow up of 32 (range 6-69) months, overall response rate was 57%
(CR  43%). Overall, 26 patients are alive; 14 in CR, 4 in PR, 4
with stable disease, and 4 with progressive disease (PD). Seven
patients died from PD, 9 from infectionsGVHD, 2 from cardiac
problems, 1 from multiorgan failure, 1 from metastatic lung can-
cer, and 1 from rejection and aplasia. Estimated 2-year rates of
non-relapse mortality, relapse-related mortality, progression free
survival, and overall survival (OS) were 29%, 15%, 49%, and 56%
respectively (Table 1). Projected 4-year OS was 47%. Conclusion:
NM-HCT provides powerful graft–versus–leukemia activity in
CLL and should be explored in phase II trials for treatment of pts
with FLU-refractory disease.
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ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT) FOR THE
TREATMENT OF CHILDREN WITH VERY HIGH RISK ACUTE LYMPHO-
BLASTIC LEUKEMIA (ALL) IN FIRST REMISSION (CR1)
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Children with very high risk ALL treated with chemotherapy
only have an expected disease-free survival of 20-40%, and are
therefore candidates for allogeneic BMT. Between August 1988
and January 2002, eighteen patients received an allogeneic BMT
for the treatment of very high risk ALL in CR1. They were 10
males and 8 females, aged 1.5–19.2 years (median 11.6). The very
high risk features of the patients were as follows: Unfavorable
cytogenetics with t(9;22) N  2, or infant with t(4;11) N  1; very
high white count at diagnosis (200,000/mm3) N 5; poor initial
response to induction chemotherapy [25% blasts on day 7 or
5% blasts on day 14 and/or day 28] N  10; hypodiploidy
N  2. Three patients had more than one very high-risk feature.
Patients received bone marrow from HLA-matched siblings
(N  9) or unrelated donors (N  9). Cytoreductive regimens
included: hyperfractionated total body irradiation (HF-TBI) 1,375
or 1,500 cGy and cyclophosphamide (CY) 60 mg/Kg/day 2 [N
6], or HF-TBI 1,375 or 1,500 cGy, Thiotepa (Thio) 5 mg/Kg/
day  2 and CY 60 mg/Kg/day  2 [N  10]. In addition two
patients received other regimens: busulfan and melphalan (N  1),
or HFTBI, Thio and etoposide (N  1). Graft-versus-host disease
(GvHD) prophylaxis included T-cell depleted grafts (N  10) or
unmodiﬁed grafts with cyclosporin  methotrexate or steroids
(N  8).
With a median follow-up of 4.7 years (range 1.5-14.7), the overall
survival and disease-free survival of the entire cohort were respec-
tively 84% and 83% respectively. Two patients relapsed 4.9 and 18
months post BMT and one patient died of an accidental death
(head trauma) 11.3 months post BMT. Two patients, both recip-
ients of unmodiﬁed grafts developed grade 2 GvHD that resolved.
In summary, the outcome of allogeneic BMT for children with
very high risk ALL in CR1 appears to be superior to that with
chemotherapy (reported as 20-40%). The use of hyperfractionated
TBI, Thio and CY followed by T-cell depleted grafts from related
or unrelated donors was associated with a very good outcome
(10/10 pts alive, disease-free) and no GvHD.
Table. CLL Patients Treated with NM Conditioning and HCT with
MRD and URD
MRD
(n  33)
URD
(n  14)
Acute GVHD grades II,
III, and IV
36%, 15%,
and 3%
43%, 14%,
and 0%
Two-year Chronic
extensive GVHD
44% 61%
Median follow-up (range) 37 (7-69)
months
19 (5-39)
months
Overall response rate
(CR)
55% (40%) 64% (50%)
Alive patients 7 CR, 2 PR,
4 stable,
3PD
7 CR, 2 PR,
1 PD
Two-year NRM 31% 23%
Two-year relapse-related
mortality
16% 8%
Two-year PFS 45% 62%
Two-year OS 53% 70%
NRM, non-relapse mortality; PFS, progression-free survival.
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